Skip to content
Head to head

Vericel vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: VCEL · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

VCEL +45.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals trades cheapest on trailing earnings; Vertex Pharmaceuticals earns the most per share.
VCELVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price57.52515.02
Change today-1.27%-1.08%
1-year return+52.0%+22.0%
Market cap$2.94B$130.58B
52-week range28.95 – 59.75412.27 – 568.67
Valuation
P/E (TTM)89.8833.14
P/E percentile, own 5-yr range50th99th
P/B7.646.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)0.3215.32
Net profit (TTM)$16.33M$3.88B
Revenue (TTM)$324.17M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+26.5%+11.8%
Gross margin74.5%85.5%
Operating margin8.3%33.1%
Net margin10.3%30.7%
Free cash flow (TTM)$57.89M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership109.6%96.8%
Insider activity (12mo)19 buy / 31 sell28 buy / 22 sell
Short interest (% of float)10.5%1.9%
Analyst consensus83% buy / 17% hold (6)95% buy / 5% hold (21)
Analyst price target$66 (+15%)$624 (+21%)
StockVane view
StockVane Quant RatingC (86)C (68)
Company
Employees3986,400
Founded19891989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.